Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Malignant Disease × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 362 Ovarian Neoplasms 98 Lung Neoplasms 97 Neoplasms 84 Small Cell Lung Carcinoma 68 Breast Neoplasms 59 Neoplasm Metastasis 48 Triple Negative Breast Neoplasms 44 Parkinson Disease 4, Autosomal Dominant Lewy Body 41 Fallopian Tube Neoplasms 38 Squamous Cell Carcinoma of Head and Neck 33 Carcinoma 30 Endometrial Neoplasms 29 Uterine Cervical Neoplasms 28 Colorectal Neoplasms 24 Carcinoma, Ovarian Epithelial 23 Head and Neck Neoplasms 19 Carcinoma, Transitional Cell 18 Urinary Bladder Neoplasms 17 Advanced Solid Tumors 16 Recurrence 15 Melanoma 14 Stomach Neoplasms 13 Peritoneal Neoplasms 13 Pancreatic Neoplasms 12 Adenocarcinoma 11 Lung Diseases 9 Glioblastoma 9 Carcinoma, Squamous Cell 9 Thoracic Neoplasms 8

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡